医学
溃疡性结肠炎
组织学
临床试验
疾病
内科学
内窥镜检查
病理
胃肠病学
作者
Thomas Chateau,Roger Feakins,Aude Marchal-Bressenot,Fernando Magro,Silvio Danese,Laurent Peyrin‐Biroulet
标识
DOI:10.14309/ajg.0000000000000437
摘要
In recent years, the therapeutic goals in ulcerative colitis (UC) have become increasingly stringent. Histological features seem to be a reliable predictor of disease outcomes after therapy, and histological remission (HR) is the new frontier in the treatment of UC. Here, we first provide a historical perspective before reviewing indexes in the era of biologics; histology as a treatment goal in UC trials; the poor correlation between symptoms, endoscopy, and histology; and the impact of histology on disease outcomes. HR seems to be a promising end point for the treatment of UC because it is typically associated with better outcomes. Two new validated indexes are available to assess histology more accurately in trials, and they may also be applicable to clinical practice. Additional interventional trials are now necessary to establish definitions of HR and its potential for disease modification.
科研通智能强力驱动
Strongly Powered by AbleSci AI